Acute myeloid leukaemia

Long-term outcome in acute myelogenous leukemia autografted with mafosfamide-purged marrow in a single institution: adverse events and incidence of secondary myelodysplasia

A Abdallah¹, G Egerer¹, RM Weber-Nordt¹, M Körbling², R Haas³ and AD Ho¹

¹Department of Medicine V, University of Heidelberg, Heidelberg, Germany; ²Department of Blood and Marrow Transplantation, MD Anderson Cancer Center, University of Texas, Houston, Texas, USA; and ³Department of Medicine, Heinrich Heine University, Düsseldorf, Germany

Summary:

We have analyzed the long-term outcome and toxicities in 98 patients with high-risk acute myelogenous leukaemia (AML) who were treated with autologous bone marrow transplantation (ABMT) and monitored for a median observation period of 11.67 years. Between 1983 and 1994, 98 patients in our institution in first or second and higher complete remission (CR) underwent total body irradiation and high-dose cyclophosphamide prior to ABMT purged with mafosfamide. Twenty-seven out of the 90 evaluable patients (30%) were alive and in continuous CR for a median of 11.67 years (range, 6.39–15.53) after ABMT and could be considered as ‘cured’. Among the 90 patients, 39 were transplanted at first CR and had a significantly higher survival rate than those transplanted at ≥2 CR. Younger patients (<40 years) had a better prognosis and patients with FAB M1–4 had a more favorable outcome than those with M5. Long-term complications included four patients with cardiac complications, two with renal insufficiency. Five developed HCV infections, four myelodysplastic syndrome. The incidence of cataract among the long-term survivors was 44.4%. Therefore, a significant number of adult patients with AML in first CR derived long-term benefit from ABMT, despite the risks of a few long-term complications and of MDS (4.4%).

Keywords: autologous bone marrow transplantation (ABMT); purging; long-term outcome; long-term toxicity; secondary myelodysplasia

Although the rate of complete remission (CR) for adult patients with acute myelogenous leukemia (AML) treated with conventional chemotherapy ranges between 65 and 80%, the disease-free survival at 5 years remains disappointingly low, and ranges between 10 and 15% in patients >55 years and 20–40% in younger patients.¹–⁷

Allogeneic bone marrow transplantation has been proven to induce long-term cure. For those without a suitable donor, autologous bone marrow transplantation (ABMT) has been increasingly used as a treatment strategy, either as part of post-remission therapy for patients with intermediate and high risks, or after successful re-induction therapy for relapse.⁸–¹⁴

One of the major limitations of ABMT is the presence of residual leukemic cells in the autologous graft. One approach to this problem is the ex vivo treatment of the autograft to eradicate these leukemic cells yet spare the normal and primitive hematopoietic stem cells.¹⁵–¹⁹

Whereas most reports on ABMT, with or without purged marrow, focus on the encouraging results in terms of survival and disease free survival, very few data are available on the long-term adverse events associated with ABMT and the outcome after a follow-up of more than 10 years.

Patients and methods

Patient eligibility

Patients had to have a diagnosis of AML based on the morphologic examination of bone marrow aspirate or biopsy, as well as peripheral blood smear. The subtypes were classified according to the criteria defined in the French–American–British (FAB) system of classification of acute leukemia.²⁰

Between July 1983 and November 1994, 98 patients with AML in first or subsequent CR received ABMT at our institution. They were mostly referred from other institutions and were primarily treated according to the German Multicenter Acute Myeloid Leukemia Trial.²¹ Patients in first CR were referred for ABMT mostly because of the presence of poor risk factors at the time of diagnosis (high WBC, elevated LDH). Patients in relapse were treated either with NOVE²² or with other equivalent salvage regimens. Indications for ABMT were made by the corresponding centers. The patients were analyzed for outcome, toxicities and prognostic factors (age, gender, FAB classification, status of the disease, etc.).
at transplant, time from diagnosis to transplantation, marrow dose of TNC/kg). None of these patients received hematopoietic growth factors (G-CSF/GM-CSF/SCF) or peripheral blood stem cell transplantation.

In the majority of patients, the marrow was harvested after the last course of consolidation chemotherapy in the same remission status as when the transplant was performed.

The database was checked, the survivors were interviewed, and corrections made when necessary from April to September 2000. The study protocol was approved by the Joint Committee on Clinical Investigation of Heidelberg University, and informed consent was obtained from patients before entering the study.

**Patient characteristics**

Of the total of 98 patients, eight were lost to follow-up and sufficient information could not be retrieved. Of the 90 patients that could be evaluated (Table 1), 50 were male and 40 were female. Median age at the time of transplantation was 37 years (range, 16–53). Distribution within the FAB classification was as follows: M1, 20%; M2, 19%; M3, 14.4%; M4, 31.1%; M5, 13.3%; and undetermined or missing 2.2%. Status at the time of transplantation was as follows: CR1, 43.3%; CR2, 45.5%; CR3, 10%; CR4, 1.1%. The median interval between time of diagnosis and time of transplantation was 15.6 months (range, 3.7–68.1).

### Table 1  Patient characteristics

| Age               | Median (range) | 37 years (16–53) |
|-------------------|----------------|------------------|
| <=40              | n = 56         |                  |
| >40               | n = 34         |                  |
| Sex               | M:F            | 50:40            |
| FAB classification| M1             | 18               |
|                  | M2             | 17               |
|                  | M3             | 13               |
|                  | M4             | 28               |
|                  | M5             | 12               |
|                  | NA             | 2                |
| Remission status  | CR1            | 39               |
|                  | CR2            | 41               |
|                  | CR3            | 9                |
|                  | CR4            | 1                |
| Marrow TNC-dose/kg| <1.0 × 10⁸      | 47               |
|                  | ≥1.0 × 10⁸     | 38               |
|                  | NA             | 5                |
|                  | Median (range) | 0.9 × 10⁸ (0.24–2.85 × 10⁸) |
| Interval diagnosis-transplantation (months)| Median (range) | 15.6 (3.7–68.1) |

FAB = French–American–British; M = male; F = female; TNC = total nucleated cell; CR = complete remission; n = number; NA = not available.

### Marrow processing

All bone marrow grafts were collected, treated with mafosfamide, washed, and cryopreserved. They were then thawed at 42°C in a water-bath and immediately infused into the patient’s central line without further manipulation. The marrow cell suspension was depleted of RBCs and neutrophils using a buffy-coat and a Ficoll–Metrizoate (FM) gradient centrifugation method as described by Gilmore et al. 23 The final cell suspension was washed twice using minimal essential medium (S-MEM), supplemented with ABO compatible human plasma (50%), and adjusted to a concentration of 2 × 10⁷ WBC/ml. Mafosfamide was added at a median dose of 70 μg/2 × 10⁷ WBC (range, 60–80) according to the individual sensitivity of granulocyte–macrophage colony-forming units, as described previously. 24 The marrow suspension was incubated with agitation at 37°C for 30 min. To terminate the cytotoxic effect of mafosfamide, the cell suspension was washed once at 4°C, resuspended with ABO compatible human plasma to a final volume of 200 ml, and transferred to four freezing bags (DELMED, Canton, MA, USA), 50 ml per bag. Fifty milliliters of cold S-MEM supplemented with 20% DMSO was added to each bag. The cell suspension was then immediately frozen at a controlled rate of 1 to 2°C per min from 10°C to −70°C, and at 7°C per min to −100°C (BV-10 Biological Freezer; Cryoson, Krefeld, Germany).

### Conditioning regimen

High-dose therapy consisted of cyclophosphamide 50 mg per kg body weight (BW) intravenously on 4 consecutive days and hyperfractionated total body irradiation (TBI), at a median dose of 14.4 Gy (range, 12.1–16.7). One patient was treated with cyclophosphamide at the above doses and busulphan orally 4 mg per kg BW on 4 consecutive days because of previous radiation therapy. All patients were treated with prophylactic acyclovir until day 100 post autografting, as described previously. 24

### Statistical analysis

A series of variables were studied, including age, gender, FAB classification, status at time of ABMT, time from diagnosis to transplantation and risk factors using the log rank test. 25

Event-free survival (EFS) was defined as survival without evidence of leukemia and is measured from the time of ABMT. To evaluate the probability of relapse, patients dying either from direct toxicity of the procedure or from any other cause not related to leukemia were censored. All variables were analyzed for their effect on the probabilities of relapse, EFS and overall survival (OS) using the methods of Kaplan and Meier. 26
Results

Hematologic recovery

The median number of total nucleated cells (TNC) transfused per kg was $0.9 \times 10^8$ (range, 0.24–2.85 $\times 10^8$), and that of mononuclear cells (MNC) transfused per kg was $0.42 \times 10^8$ (range, 0.11–1.50 $\times 10^8$). The number of cells that were reinfused was given as counted at the time of cryopreservation.

Patients whose marrow harvest yielded <1.0 $\times 10^8$ TNC/kg had a 100 day mortality of 16% while patients whose marrow harvest contained >1.0 $\times 10^8$ TNC/kg had a 100 day mortality of 8.6%. There were otherwise no significant differences between patients whose marrow harvest yielded >1.0 $\times 10^8$ TNC/kg or less as regards disease-free survival or overall survival ($P = 0.37$, $P = 0.49$, respectively).

The recovery of the total leukocyte count to >1000/µl occurred at a median of 27 days (range, 12–81). Neutrophil recovery to >500/µl occurred at a median of 28 days (range, 13–81). The median recovery of platelet count to >20 000/µl without substitution was 48 days (range, 11–356). There was a significant correlation between the dose of TNC/kg and granulocyte engraftment >0.5 $\times 10^9$ ($P = 0.01$) but not platelet recovery.

Nine patients died before reaching hematologic recovery (neutrophils >500/µl); seven due to transplant-related causes and two due to early relapse. Three patients showed pancytopenia with graft failure and died within the first 100 days after transplantation. Seven patients showed delayed platelet recovery and an unmaintained platelet count of >20 000/µl was reached ranging from 107 to 356 days.

Immediate toxicity and adverse events

All patients experienced mild to severe nausea and vomiting at the time they received high-dose cyclophosphamide. Within the first 100 days after transplantation, four patients developed hemorrhagic cystitis (none fatal), two developed veno-occlusive disease (VOD); one died and the other recovered. Twelve developed pulmonary complications (including two interstitial pneumonitis and three fungal pneumonias) and one patient died due to acute respiratory distress syndrome (ARDS). Five of the 12 with pulmonary complications died (three of fungal pneumonia and one each of interstitial pneumonitis and pneumonia). The diagnosis of interstitial pneumonitis was made by X-ray and no organism was identified. One patient developed congestive cardiac failure and died. Four patients died due to sepsisemia (one of four from candida sepsis). Overall, there were 12 (13.3%) cases of therapy-related mortality within the first 100 days.

Within the first year, there were 39 deaths; 11 patients (12.2%) died due to early relapse in the first 6 months after transplantation and 13 patients (14.4%) died due to relapse in the following 6 months. A very uncommon observation was a patient who developed acute graft-versus-host disease (GVHD) of the liver (grade IV) after transplantation with a maximum bilirubin level of 22.0 mg/dl. In addition, this patient suffered from acute GVHD manifestations of the skin (grade II–III) and died as a sequel of these complications 110 days after transplantation.

Long-term outcome

The probabilities of event-free survival (EFS) and overall survival (OS) are demonstrated in the Figure 1a and b. Most relapses (37/45) occurred within the first 30 months. As of 15 March 2000, 27 patients (30%) were alive and well in continuous complete remission (CCR) at the last follow-up 6.4–15.5 years (median 11.7) after ABMT (Table 2).

We analyzed the prognostic factors that are associated with favorable long-term outcome. Younger autografted patients <40 years (Figure 2) had a better outcome than those >40 years (EFS, $P = 0.023$; OS, $P = 0.013$). Patients with FAB M1–4 had a more favorable outcome than those with M5 (EFS, $P = 0.03$; OS, $P = 0.05$). There was no significant difference in gender or time from diagnosis to transplantation between long-term responders and those who died. Patients autografted in CR1 had a more favorable long-term outcome than those transplanted in second or later remissions. Figure 3 shows that the actuarial 5 year probability of event-free survival in patients in CR1 is 48.3% (EFS, $P = 0.018$; OS, $P = 0.013$).

Long-term toxicity

Long-term toxicity is defined as toxicity occurring 6 months or later after transplantation.

Partial engraftment failure: There were seven patients (7.7%) with persistent thrombocytopenia for more than 100 days after ABMT. Four patients with thrombocytopenia recovered on days 193, 356, 323 and 201, respectively, and were alive in CCR at the completion of this study. Two ultimately developed secondary MDS and died as a consequence of MDS at 32.8 and 115.0 months after transplantation. One died of relapse of AML 148 months after transplantation.

Cardiac toxicity: Four patients (4.4%) suffered from grade II–IV (according to WHO) cardiac toxicity. The pretransplant examination revealed no cardiac abnormalities for these patients. In two patients, the cardiac insufficiency (grade II and III) was transient and reversible, and they were alive and performing well at 127 and 141 months after transplantation. The third patient had cardiac insufficiency grade II (WHO) and died at 11 months after transplantation due to relapse, while the last patient developed cardiac insufficiency grade IV and died due to heart failure at 13 months after transplantation.

Renal toxicity: Three patients developed long-term renal complications. Two patients (2.2%) had chronic renal insufficiency, of whom one required hemodialysis. He developed renal failure 86 months after ABMT, was treated with dialysis for 26 months and died 112 months after transplantation due to renal complications. The cause of the renal failure was not known but was most probably unrelated to transplantation. The other patient required no specific treatment but died due to relapse of AML 148 months after transplantation.
transplantation. The third patient developed hemorrhagic cystitis after ABMT; then chronic interstitial nephritis with acute renal tubular necrosis, probably related to high-dose cyclophosphamide. He died (in CR) of multi-organ failure 8 months after transplantation.

**Hepatic toxicity:** Five patients developed antibodies against hepatitis C virus between days 100 and day 360 after transplantation. Three of them are alive and in CCR 102, 153 and 166 months after transplantation. Of the other two, one developed liver cirrhosis and died in CR 17 months after transplantation due to liver failure, and the other developed secondary hemochromatosis of the liver and died due to relapse 118 months after transplantation. In addition, another patient developed hepatic siderosis with evidence of bone marrow siderosis 7 months after transplantation and died 1 month later. The cause of hepatic siderosis was not clear.

**Pulmonary toxicity:** One patient developed bronchial asthma 22 months after transplantation, probably unrelated to ABMT. This patient underwent bronchodilator treatment and was doing well in CCR at 120 months after transplantation.

**Dermatological toxicity:** One patient had chronic GVHD of skin grade II and died 8 months after transplantation due to renal complications as mentioned above. One patient developed neurodermatitis after transplantation and was alive in CCR 78 months after transplantation. Four patients suffered from reactivation of herpes zoster infection 10, 86, 112 and 140 months after transplantation.

**Neurotoxicity:** Two patients developed generalized seizures of unknown etiology 7 and 12 months after transplantation; both died due to relapse of leukemia at 9 and 16.7 months, respectively, after transplantation. Another patient had peripheral neuropathy and was alive in CCR 141 month after transplantation. One patient developed restless leg syndrome after transplantation with muscle twitches in both legs, mostly at night. Investigations revealed no abnormalities in serum electrolytes, magnesium, iron, hormones or any neuro-muscular disorder. This patient underwent different kinds of treatment without success. She was in CCR and alive for 135 months after transplantation.

**Susceptibility for infections:** Among the 27 long-term survivors, 13 patients (48%) reported increased susceptibility to viral infections, mostly the common cold, influenza and herpes zoster virus. Among these, five patients (three male, two female) suffered from recurrent urinary tract infections and four patients from recurrent pneumonia.

**Ocular toxicity:** Among the long-term survivors, 12 of 27 patients (44.4%) developed cataracts in both eyes after a median of 76 months (range, 48–140) after TBI. One patient developed photosensitivity 60 months after transplantation without cataract formation. She was alive and doing well in CCR 176 months after transplantation.
Table 2  Characteristics of 27 AML long-term survivors

| Patient ID number | Age (months) | Sex | FAB | Remission status at Tx | Marrow TNC-dose/kg × 10⁹ | Interval Dx–Tx (months) | Date of Tx | EFS (years) |
|-------------------|--------------|-----|-----|------------------------|--------------------------|-------------------------|------------|------------|
| 01                | 27           | M   | M3  | CR3                    | 1.33                     | 68.1                    | 06.08.87   | 12.8       |
| 02                | 36           | F   | M1  | CR1                    | 0.62                     | 7.2                     | 03.12.86   | 13.5       |
| 07                | 16           | F   | M2  | CR1                    | 0.65                     | 7.0                     | 13.09.90   | 9.6        |
| 10                | 33           | F   | M4  | CR1                    | 0.35                     | 12.5                    | 10.07.86   | 13.9       |
| 14                | 17           | F   | M4  | CR1                    | 0.67                     | 4.2                     | 25.11.93   | 6.4        |
| 16                | 34           | M   | M4  | CR1                    | 0.72                     | 10.1                    | 16.10.86   | 13.6       |
| 17                | 48           | F   | M4  | CR2                    | 0.74                     | 18.9                    | 21.07.88   | 11.8       |
| 22                | 42           | F   | M4  | CR2                    | 0.61                     | 33.4                    | 29.06.89   | 10.9       |
| 24                | 42           | F   | M2  | CR3                    | 1.03                     | 42.4                    | 26.09.85   | 14.7       |
| 26                | 18           | M   | M2  | CR1                    | 0.58                     | 27.1                    | 08.04.93   | 7.0        |
| 27                | 26           | F   | M4  | CR2                    | 2.07                     | 22.4                    | 04.10.91   | 8.6        |
| 28                | 30           | F   | M4  | CR1                    | NA                       | 3.8                     | 22.11.84   | 15.5       |
| 40                | 22           | M   | M2  | CR1                    | 1.36                     | 11.0                    | 10.04.86   | 14.6       |
| 44                | 23           | M   | M4  | CR2                    | 2.01                     | 65.5                    | 21.05.86   | 14.0       |
| 50                | 21           | M   | M4  | CR1                    | 1.22                     | 9.3                     | 21.10.87   | 12.6       |
| 58                | 40           | F   | M4  | CR1                    | 0.86                     | 9.3                     | 09.10.86   | 13.6       |
| 59                | 29           | M   | M1  | CR2                    | 0.63                     | 20.3                    | 02.04.92   | 5.8        |
| 63                | 37           | M   | M1  | CR1                    | 1.23                     | 6.9                     | 26.10.89   | 10.5       |
| 71                | 28           | F   | M1  | CR1                    | 0.78                     | 11.0                    | 10.04.86   | 14.6       |
| 73                | 46           | F   | M1  | CR2                    | NA                       | 29.4                    | 31.10.91   | 8.5        |
| 81                | 39           | M   | NA  | CR1                    | 0.50                     | 6.3                     | 11.07.91   | 8.8        |
| 83                | 38           | F   | M1  | CR1                    | 1.76                     | 6.6                     | 14.09.89   | 10.7       |
| 89                | 22           | M   | M1  | CR2                    | 1.50                     | 9.2                     | 16.01.86   | 14.4       |
| 92                | 22           | F   | M1  | CR1                    | 1.84                     | 5.0                     | 30.01.86   | 14.3       |
| 94                | 40           | M   | M3  | CR1                    | 0.48                     | 18.8                    | 15.09.88   | 11.7       |
| 95                | 39           | F   | M3  | CR1                    | 2.85                     | 10.3                    | 05.01.89   | 11.4       |
| 96                | 49           | F   | M1  | CR1                    | 1.35                     | 6.8                     | 17.08.89   | 11.2       |

FAB = French–American–British; M = male; F = female; Tx = transplantation; TNC = total nucleated cell; Dx = diagnosis; EFS = event-free survival; CR = complete remission; NA = not available.

Figure 3  Correlation between remission status and DFS and OS in 90 patients autografted for AML.

Incidence of early osteoporosis after ABMT: Among the long-term survivors, two female patients (7.4%) experienced early osteoporosis without a previous family history or any other risk factors for osteoporosis. The symptoms of osteoporosis began 3 years after transplantation and became worse over time. They were transplanted at an age of 30 and 40 years and they were alive in CCR at 186.4 and 163.5 months after transplantation consecutively. The first patient had severe osteoporosis with multiple spontaneous rib fractures. She is 46 years old now and receiving therapy with fluoride, vitamin D₃, calcium and estrogen.

Reintegration into previous employment: Among the 27 long-term survivors, 13 patients (48%) resumed their previous occupation. Four patients (14.8%) took up part-time employment because of fatigue. Three patients (11%) were not able to enter into employment again after transplantation, while four patients (14.8%) preferred to receive early pension because of loss of stamina and of exhaustion after moderate work. Three female patients could not be evaluated as they were home-makers before transplantation. They were, however, able to resume their previous daily activities after transplantation.

Myelodysplasia: We observed four patients who developed myelodysplasia (MDS) 32, 46, 112 and 144 months after transplantation. The last patient, in addition to MDS, developed secondary AML with >50% blasts 146 months after transplantation. The details of these four patients are summarized in Table 3. Cytogenetic analysis in all these patients...
cases had not been undertaken initially, and it remains debatable whether the relapse was of the original disease. For the purposes of statistical analysis, we consider these patients to have died from relapse. No other secondary malignancies were observed. We considered that the risk of MDS among all 90 patients studied was 4.4%. However, if we considered the incidence of MDS only among the patients who survived more than 30 months, this would have been four cases of MDS out of 34 patients (11.8%).

**Discussion**

Many studies have suggested that ABMT might be beneficial for AML patients with high-risk factors or with recurrent disease, especially if a compatible, related donor cannot be identified. However, conclusive statements on the long-term benefits and adverse effects have been limited by the short follow-up period in most studies. In this report, we have summarized the long-term toxicities associated with the procedure as well as the outcome after a median follow-up of 11.7 years.

Among the 90 patients who were evaluable, 27 (30%) were alive and well between 6.4 and 15.5 years after ABMT. Many other authors have reported comparable rates of EFS and survival among patients with AML. It has been reported that ABMT in the second and third CR has achieved results similar to those obtained with allogeneic bone marrow transplantation.

The results of the Eastern Cooperative Oncology Group (ECOG) study and of the EORTC indicated that the outcome of ABMT in first CR rivalled that of allogeneic BMT. Long-term disease-free survival after ABMT in AML might be better than conventional-dose post-remission therapy. Present evidence suggests that maintenance chemotherapy after early consolidation without ABMT does not prolong survival in AML patients.

In the report of the European Group for Bone Marrow Transplantation (EBMT), the probability of long-term disease-free survival (DFS) was about 40% for patients autografted for acute leukemia in first complete remission (CR1) and 30%, if treated in CR2.4,9,11

Our study confirms that the probability of long-term DFS for patients autografted in first CR is significantly better than that of patients transplanted in second or higher CR (EFS, \( P = 0.018 \); OS, \( P = 0.013 \)), with 46.1% overall survival. In our hands, ABMT has therefore achieved a CCR rate that is more favorable than the rates accomplished with conventional chemotherapy. The very long-term outcome after transplantation was similar to that reported in the literature.10,12,30,31

Criticism could be raised that this was not a randomized trial and that we could not exclude selection of patients. The uncontrolled design of this retrospective study may have favored the selection of low-risk young patients. Furthermore, the significantly better prognosis of younger patients \(<40\) years (DFS, \( P = 0.023 \); OS, \( P = 0.013 \)) is an obvious bias. However, the influence of age should not be overestimated, as indicated by other authors.32,33 In the study period between 1983 and 1989, cytogenetic analysis was not generally available. Hence it was not possible to identify any relationship between chromosomal aberration with the long-term outcome after more than 10 years.

Meanwhile, a retrospective study from the registry data from the EBMT and the IBMTR showed a significant overall survival advantage of about 10% for the AML patients who were autografted with mafosfamide/4HC-purged marrow vs non-manipulated ABMT. This difference could be demonstrated 2 years after ABMT.11,27 Our data are in alignment with these observations. Obviously, these were not prospective randomized trials and should be interpreted with caution.

The emphasis of this report has been on the long-term adverse events after more than 10 years. The most significant observation is the incidence of 4.4% of myelodysplasia, which evolved at a median of 79 months (range, 32–144) after ABMT. These four patients initially showed delayed platelet engraftment with a median of 161.5 days (range, 46–323). According to the standards at the time of transplantation, all four patients had an adequate amount of TNC (median \( 0.7 \times 10^9/kg \); range, 0.39–1.1 \( \times 10^9/kg \)) in the autografts. One patient developed additional secondary AML and died shortly thereafter. The other three patients all ultimately died of the consequences of MDS.

In addition, seven patients had persistent thrombocytopenia more than 100 days after ABMT. Without the benefits of the initial cytogenetic finding or other genetic markers, the origin of the MDS cell clone remains speculative. Although there are extensive reports on the incidence of MDS after ABMT for non-Hodgkin’s lymphoma, Hodgkin’s disease and breast cancer data on the incidence of MDS in AML patients after ABMT are available.

Long-term cardiac toxicity occurred in four patients (4.4%), one of whom also died as a result of cardiac complications. Although the role of cyclophosphamide, of TBI, or of cumulation of both remains to be clarified, other
authors have reported similar rates of cardiac toxicity in patients treated with high-dose cyclophosphamide.\(^{40,41}\)

The incidence of GVHD after autologous transplantation has been reported occasionally and is probably less than 1%.\(^{42}\) We encountered two patients who had biopsy-proven GVHD. Whether this might be due to \textit{ex vivo} purging of the marrow with mafosfamide is open to speculation.

As most of our patients were transplanted in the 1980s, the rate of the HCV infection after BMT was relatively high at 5.5\% compared to 6.6\% incidence of post-transfusion hepatitis C at that time.\(^{33}\) Currently, the incidence of post-transfusion hepatitis C is much lower, almost negligible, due to the highly sensitive testing for HCV. The incidence of cataract formation after conditioning regimens containing TBI with ABMT in our study was 44\%, compared to 50\% in the reports of the European Group for Blood and Marrow Transplantation.\(^{44}\)

It is of note that a lower incidence of fatal late events was observed among long-term survivors transplanted in CR1 (1/18) as opposed to those transplanted in CR2 or CR3 (3/9). This observation suggests that additional chemotherapy regimens prior to transplantation probably have a negative impact on long-term toxicity.

For patients transplanted with mafosfamide-purged marrow, no definite ‘cut off’ value for the minimal dose of total nucleated cells (TNC) has been reported. Demirer \textit{et al}\(^{48}\) determined a significant difference in engraftment as well as in outcome for patients with acute leukemia who were transplanted with unpurged marrow using a dose of TNC $>2.0 \times 10^8$ kg. Applying a multivariate analysis to our patient population, patients with a cell dose of $>1.0 \times 10^8$ TNC/kg experienced a significantly reduced 100-day mortality compared to those transplanted with a cell dose of $<1.0 \times 10^8$ TNC/kg after adjusting for disease status and patient age at transplant. There was, however, no statistically significant difference in long-term EFS or overall survival between the two groups ($P = 0.37$, $P = 0.49$, respectively). Although a correlation between the dose of TNC/kg and engraftment with a peripheral blood granulocyte count of $>0.5 \times 10^9$ was found ($P = 0.01$), no such relationship with platelet recovery could be established. Thus, in contrast to the report of Gorin \textit{et al}\(^{46}\) we could not find any relationship between cell dose and long-term outcome. However, it should be noted that Gorin analyzed the correlation between outcome and CFU-GM dose in mafosfamide-purged marrow and not the marrow dose of TNC.

In summary, our retrospective analysis shows that at a median follow-up of 11.7 years a third of adult patients with AML derived long-term benefit from high-dose chemotherapy and ABMT, albeit with significant long-term toxicities.

**Acknowledgements**

We thank Axel Benner for the excellent technical assistance in conducting the statistical evaluation of this study.

**References**

1. Bishop JF, Matthews JP, Young GA. A randomized study of high dose cytarabine in induction in acute myeloid leukemia. \textit{Blood} 1996; \textit{87}: 1710–1717.
2. Burnett AK, Goldstone AH, Stevens RM. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: results of MRC AML 10 trial. \textit{Lancer} 1998; \textit{351}: 700–708.
3. Weick JK, Kopecky KJ, Appelbaum FR \textit{et al}. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. \textit{Blood} 1996; \textit{88}: 2841–2851.
4. Mayer RJ, Davis RB, Schiffer CA \textit{et al}. Intensive postremission chemotherapy in adults with acute myeloid leukemia. \textit{New Engl J Med} 1994; \textit{331}: 896–903.
5. Fopp M, Fey MF, Bacchi M \textit{et al}. Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SACK). \textit{Ann Oncol} 1997; \textit{8}: 251–257.
6. Visani G, Bernasconi P, Boni M \textit{et al}. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukaemia – analysis of 848 patients. \textit{Leukemia} 2001; \textit{15}: 903–909.
7. Harousseau JL, Cahn JY, Pignon B \textit{et al}. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukaemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). \textit{Blood} 1997; \textit{90}: 2978–2986.
8. Gorin NC, Labopin M, Meloni G \textit{et al}. Autologous bone marrow transplantation for acute myeloblastic leukaemia in Europe: further evidence of the role of marrow purging by mafosfamide. European Co-operative Group for Bone Marrow Transplantation (EBMT). \textit{Leukemia} 1991; \textit{5}: 896–904.
9. Labopin M, Gorin NC. Autologous bone marrow transplantation in 2502 patients with acute leukaemia in Europe: a retrospective study. \textit{Leukemia} 1992; \textit{6} (Suppl. 4): 95–99.
10. Zittoun RA, Mandelli F, Willems E \textit{et al}. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukaemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups. \textit{New Engl J Med} 1995; \textit{332}: 217–223.
11. Gorin NC, Labopin M, Fouillard L \textit{et al}. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA-identical related donor in acute myelocytic leukaemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT). \textit{Bone Marrow Transplant} 1996; \textit{18}: 111–117.
12. Gorin NC. Autologous stem cell transplantation in acute myelocytic leukemia. \textit{Blood} 1998; \textit{92}: 1073–1090.
13. Cassileth PA, Lynch E, Hines JD \textit{et al}. Varying intensity of postremission therapy in acute myeloid leukemia. \textit{Blood} 1992; \textit{79}: 1924–1930.
14. Cassileth PA, Harrington DP, Appelbaum FR. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. \textit{New Engl J Med} 1998; \textit{339}: 1649–1656.
15. Gorin NC, Aegerter P, Auvert B \textit{et al}. Autologous bone marrow transplantation for acute myelocytic leukaemia in first remission: an European survey of the role of marrow purging. \textit{Blood} 1990; \textit{75}: 1606–1614.
16 Yeager AM, Rowley SD, Kaizer H, Santos GW. Ex vivo chemopurging of autologous bone marrow with 4-hydroperoxycyclophosphamide to eliminate occult leukemic cells. *Am J Pediatr Hematol/Oncol* 1990; 12: 245–256.

17 Laporte JP, Douay L, Lopez M et al. One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10-year single institute experience. *Blood* 1994; 84: 3810–3818.

18 Miyamoto T, Nagafuji K, Harada M. Quantitative analysis of AML 1/ETO transcripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelogenous leukemia. *Br J Haematol* 1995; 91: 132–138.

19 Brenner MK, Rill DR, Moen RC. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. *Lancet* 1993; 341: 85–86.

20 Bennett JM, Catovsky D, Daniel MT et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group. *Ann Intern Med* 1985; 103: 620–625.

21 Buchner T, Urbanitz B, Hiddemann W. Intensified induction and consolidation with and without maintenance chemotherapy for acute myeloid leukemia: two multicenter studies of the German AML Cooperative Group. *J Clin Oncol* 1985; 3: 1583–1589.

22 Ho AD, Lipp T, Ehniger G et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia – an active and well-tolerated regimen. *J Clin Oncol* 1988; 6: 213–217.

23 Gilmore MJ, Prentice HG, Blacklock HA et al. A technique for rapid isolation of bone marrow mononuclear cells using Ficoll-Metrizoate and the IBM 2991 blood cell processor. *Br J Haematol* 1982; 50: 619–626.

24 Köhring M, Hunstein W, Fliedner TM et al. Disease-free survival after autologous bone marrow transplantation in patients with acute myelogenous leukemia. *Blood* 1989; 74: 1898–1904.

25 Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. *Br J Cancer* 1977; 35: 1–39.

26 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 1958; 53: 457–481.

27 Selvaggi KJ, Wilson JW, Mills LE et al. Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow. *Blood* 1994; 83: 1698–1705.

28 Petersen FB, Lynch MHE, Clift RA et al. Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission. *J Clin Oncol* 1993; 11: 1353–1360.

29 Sauter C, Berchtold W, Foop M. Acute myelogenous leukemia: maintenance chemotherapy after early consolidation does not prolong survival. *Lancet* 1984; 1: 379–382.

30 Chopra R, Goldstone AH, McMillan AK et al. Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: the British autograft group experience. *J Clin Oncol* 1991; 9: 1840–1847.

31 Cassileth PA, Andersen J, Lazarus HM et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. *J Clin Oncol* 1993; 11: 314–319.

32 Bassan R, Raimondi R, Lerede T et al. Outcome assessment of age group-specific (+/- 50 years) post-remission consoli-

dation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia. *Haematologica* 1998; 83: 627–635.

33 Kusnierz-Glaz CR, Schlegel PG, Wong RM et al. Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies. *J Clin Oncol* 1997; 15: 18–25.

34 Miller JS, Arthur DC, Litz CE. Myelodysplastic syndrome after autologous bone marrow transplantation an additional late complication of curative cancer therapy. *Blood* 1994; 83: 3780–3786.

35 Darrington DL, Vose JM, Anderson JR et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. *J Clin Oncol* 1994; 12: 2527–2534.

36 Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. *Blood* 2000; 95: 3273–3279.

37 Bhatia S, Ramsay NK, Steinbuch M. Malignant neoplasms following bone marrow transplantation. *Blood* 1996; 87: 3633–3639.

38 Sobecks RM, Le Beau MM, Anastasi J, Williams SF. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. *Bone Marrow Transplant* 1999; 23: 1161–1165.

39 Stone RM, Neuberg D, Soiffer R. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin’s lymphoma. *J Clin Oncol* 1994; 12: 2535–2542.

40 Baello EB, Ensberg ME, Ferguson DW et al. Effect of high-dose cyclophosphamide and total-body irradiation on left ventricular function in adult patients with leukemia undergoing allogeneic bone marrow transplantation. *Cancer Treat Rep* 1986; 70: 1187–1193.

41 Nieto Y, Cagnoni PJ, Bearman SI et al. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer. *Biol Blood Marrow Transplant* 2000; 6: 198–203.

42 Saunders MD, Shulman HM, Murakami CS et al. Bile duct apoptosis and cholestasis resembling acute graft-versus-host disease after autologous hematopoietic cell transplantation. *Am J Surg Pathol* 2000; 24: 1004–1008.

43 Wang YJ, Lee SD, Hwang SJ et al. Incidence of post-transfusion hepatitis before and after screening for hepatitis C virus antibody. *Vox Sang* 1994; 67: 187–190.

44 Belkacemi Y, Labopin M, Vernant JP et al. Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukemia in complete remission: a study of the European Group for Blood and Marrow Transplantation. *Int J Radiat Oncol Biol Phys* 1998; 41: 659–668.

45 Demirer T, Gooley T, Buckner CD et al. Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation. *Bone Marrow Transplant* 1995; 15: 907–913.

46 Gorin NC, Labopin M, Laporte JP et al. Importance of marrow dose on posttransplant outcome in acute leukemia: models derived from patients autografted with mafosfamide-purged marrow at a single institution. *Exp Hematol* 1999; 27: 1822–1830.